Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04704921 · ClinicalTrials.gov registry record · Phase 2

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

A Phase 2 study of Neovascular Age-related Macular Degeneration and Wet Age-related Macular Degeneration, sponsored by AbbVie.

Recruiting
Registry status
Phase 2
Development phase
630
Enrollment target
20
Study locations

NCT04704921: Recruiting Phase 2 study of Neovascular Age-related Macular Degeneration and Wet Age-related Macular Degeneration, sponsored by AbbVie.

NCT04704921 is a Phase 2 study of Neovascular Age-related Macular Degeneration and Wet Age-related Macular Degeneration that is actively recruiting participants, run by AbbVie. The registered enrollment target is 630 participants, above the 389-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04704921, a Phase 2 study of Neovascular Age-related Macular Degeneration and Wet Age-related Macular Degeneration, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 2
Development phase
630 participants
Enrollment target
20
Study locations

Study Summary

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (anti-VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to maintain or prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every 4 to 16 weeks in frequency, to maintain efficacy. Due to the burden of these treatments, patients often experience a decline in vision with reduced frequency of treatment over time.

Primary Outcome

BCVA measured by Early Treatment Diabetic Retinopathy Study (ETDRS)

Conditions Studied

Neovascular Age-related Macular Degeneration Wet Age-related Macular Degeneration Choroidal Neovascularization AMD Wet AMD wAMD nAMD CNV Neovascular AMD

Interventions

  • GENETIC ABBV-RGX-314
  • BIOLOGICAL Ranibizumab (LUCENTIS®)

Study Locations (20)

California

  • Retina Vitreous Assoc Med Grp /ID# 256299 - Beverly Hills
  • Retinal Diagnostic Center /ID# 256137 - Campbell
  • The Retina Partners - Encino /ID# 256054 - Encino
  • Retina Consultants of Orange County /ID# 256152 - Fullerton
  • Salehi Retina Institute /ID# 263485 - Huntington Beach
  • UC Irvine/Gavin Herbert Eye Institute /ID# 256145 - Irvine
  • Northern California Retina Vitreous Associates Medical Group, Inc /ID# 256298 - Mountain View
  • UCLA Doheny Eye Center /ID# 256120 - Pasadena
  • California Eye Specialists Medical Group Inc. /ID# 256079 - Pasadena
  • Retina Consultants of San Diego /ID# 256021 - Poway
  • Retinal Consultants Medical Group /ID# 256047 - Sacramento
  • West Coast Retina /ID# 256448 - San Francisco
  • University of California, San Francisco /ID# 256130 - San Francisco
  • Orange County Retina Medical Group /ID# 256073 - Santa Ana
  • California Retina Consultants - Santa Barbara /ID# 256017 - Santa Barbara

Arizona

  • Retinal Research Institute /ID# 256019 - Phoenix
  • Barnet Dulaney Perkins Eye Center - Sun City /ID# 256055 - Sun City

Colorado

  • Retina Consultants of Southern Colorado /ID# 256069 - Colorado Springs
  • Southwest Retina Research Center /ID# 256136 - Durango

Arkansas

  • University of Arkansas for Medical Sciences /ID# 271290 - Little Rock

Trial Details

FieldValue
Enrollment Target 630 participants
Start Date 2020-12-29
Est. Completion 2027-11
Phase Phase 2
AbbVie

526 total trials

What NCT04704921 shows while recruiting

NCT04704921 is an interventional study that assigns participants to a tested intervention. The registered 630 participants enrollment target is mid-sized for trials with a published cap, above the 389-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (62% higher).

The record links to 9 conditions, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which ABBV-RGX-314 is the first listed.

NCT04704921 names 20 study sites across 4 states, led by California, Arizona, Colorado.

Frequently Asked Questions

What is clinical trial NCT04704921 about?

NCT04704921 is a clinical study titled "Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD". ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a signific...

What is the current status of trial NCT04704921?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 630 participants. The study started on 2020-12-29. Estimated completion is 2027-11.

What conditions does trial NCT04704921 study?

This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration, Choroidal Neovascularization, AMD, Wet AMD.

What interventions are being tested in trial NCT04704921?

The interventions under investigation include: ABBV-RGX-314 (GENETIC), Ranibizumab (LUCENTIS®) (BIOLOGICAL).

Who is sponsoring clinical trial NCT04704921?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04704921 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neovascular Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04704921's enrollment target sits among peer trials

630 5th of 33 higher than 29 of 33 other Neovascular Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04707729 · 630 participants · NA

    ROX Index for the Timing of Intubation in Nasal High Flow

  • NCT05061550 · 630 participants · Phase 2

    Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • NCT05224440 · 630 participants · NA

    National Sponsorship Program for Transitioning Service Members

  • NCT05671510 · 630 participants · Phase 3

    ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04704921

Source: ClinicalTrials.gov NCT04704921, the US trial registry maintained by the National Library of Medicine. NCT04704921 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.